Abstract
e14137 Background: Colorectal cancer (CRC) is the third most common cancer in the UK with approximately 20% of patients (pts) presenting with metastatic disease. In 2008 there were over 16,000 deaths from CRC in the UK. The treatment of metastatic colorectal cancer has changed significantly over the last decade. Developments in cytotoxic agents, the use of combination chemotherapy and the introduction of biological treatments have made incremental survival gains. The UK has poorer survival rates from certain cancers when compared to its European counterparts, with a significant poor outcome of patients in the east end of London; This is thought to be due in part to the later diagnosis of cancer.Here a retrospective single centre analysis of survival data is reported in pts treated with palliative chemotherapy for locally advanced and metastatic CRC over a 10 year period. Methods: The survival data in pts with metastatic and locally advanced CRC treated between the years 2000 to 2010 was analysed. Results: 482 pts were deemed suitable for palliative chemotherapy. Pt characteristics of the analysed population was equally distributed over the years analysed. No differences in survival regarding age or gender were uncovered. A significant survival improvement was observed for the pts treated from 2007-2010. Overall survival from 2000-2002 was 11.6months (n=136), 2003-2006 10.9 months (n=174) and 2007-2010 (n=189) 16.0 months. This compares to the overall UK survival (13.7 months) and Europe(20.6 months). Conclusions: This retrospective analysis demonstrates a significant improvement in overall survival over the last 3years of pts with metastatic CRC treated at a UK tertiary referral centre. This is likely to be attributable to a variety of factors including the introduction of biological agents, developments in cytotoxic agents, the use of combination chemotherapy, improvements in supportive care and better patient selection for treatment. Updated data analysis will be made available at the meeting.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
